1 Title page

2

3 To what extent is the altitude at which we live 4 associated with 10-year cardiovascular risk? 5

6 Andrea Cevallos Guerrero^{1¶}, Heidi Angela Fernández^{1¶}, Ángela León-Cáceres^{3,4¶},
7 Luciana Armijos-Acurio², Carlos Erazo³, Ruth Jimbo-Sotomayor², Hugo Pereira-
8 Olmos³, Henry Pineda-Abarca⁵, Erika Quishpe-Narváez³, Xavier Sánchez², Carmenza
9 Sevilla³, Betzabé Tello³, Ana Torres-Castillo³, Tatiana Villacrés³, Iván Dueñas-Espín^{3&}

10 ¹ Department of Internal Medicine, Eugenio Espejo Hospital, Gran Colombia Street,
11 Quito, Ecuador.

12 ² Centro de Investigación para la Salud en América Latina (CISeAL), Facultad de
13 Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.

14 ³ Instituto de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica del
15 Ecuador (PUCE), Quito, Ecuador.

16 ⁴ Heidelberg Institute of Global Health, Faculty of Medicine, University of Heidelberg,
17 Heidelberg, Germany; Tropical Herping, Quito-Ecuador.

18 ⁵ PUCESalud, Pontificia Universidad Católica del Ecuador, Quito, Pichincha, Ecuador.

19 * Correspondence author

20 E-mail: igduenase@puce.edu.ec

21 ¶ These authors contributed equally to this work.

22 Number of words in the abstract: 247, number of words in the main text: 3990, number
23 of figures: 1, number of tables: 2, number of supporting information archives: 7;
24 number of references: 47.

25 **Abstract**

26 **Introduction:**

27 There is evidence that demonstrates lower incidence rates of cardiometabolic factors at
28 the highlands. There are no studies which correlate the altitude with formally calculated
29 cardiovascular risk by a meter-by-meter approach. Under the hypothesis that
30 cardiovascular risk is inversely associated with altitude, this study was aimed to assess
31 such association.

32 **Materials and methods**

33 Cross sectional study using data from the Ecuadorian National Health Survey of 2012.
34 We analyzed available information of adults of ≥ 40 to 60 years old who have
35 sociodemographic, anthropometric, cardiovascular risk factors, and laboratory
36 biomarkers that were included in the survey. We assessed the independent association
37 between altitude of the housing in which survey participants lived at, on a meter-by-
38 meter approach, and cardiovascular health risk at ten years, formally calculated by
39 Framingham equations.

40 **Results**

41 Linear regression model showed that participants had 0.0005 % less probability of
42 developing cardiovascular disease at 10 years *per* each increase in a meter in the altitude
43 that participants live at ($p < 0.001$), adjusted for sex, age, ethnicity, educational level,
44 availability of social security, immigrants in family, area, income quintile,
45 overcrowding (≥ 7 inhabitants in the house), any alcohol consumption, history of
46 hypertension, body mass index, hematocrit, and triglycerides.

47 Conclusion

48 From a public health perspective, altitude at which individuals live is an important
 49 health determinant of cardiovascular risk. Specifically, *per* each increase of 1000 m in
 50 the altitude that people live at, there is a reduction of almost half a percentual point in
 51 the cardiovascular risk at 10 years.

52
 53 **Keywords:** epidemiology, altitude, cardiovascular risk, cross sectional study.
 54

55 Introduction

56 Cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming the
 57 lives of approximately 17.9 million people annually [1]. They account for roughly 50%
 58 of non-communicable disease deaths [2,3] and more than three quarters of these deaths
 59 take place in low- and middle-income countries [4]. CVDs include coronary heart
 60 disease and stroke, among the most important, all of which produce substantial health
 61 and economic burden globally [2].

62 It is widely accepted that CVDs are closely related to social determinants (SDs) of
 63 health, which are defined by the World Health Organization (WHO) as “circumstances
 64 in which people are born, grow, live, work, and age, and the systems put in place to deal
 65 with illnesses” [5–7]. Scientific evidence has shown that SDs such as socioeconomic
 66 status, demographic characteristics, education, work environment, health care services
 67 and housing may be associated with the development of CVDs; however they are not
 68 routinely acknowledged during risk assessment in clinical practice [8–10]. At the same
 69 time, a lot of efforts are directed to identify and treat individual-level risk factors [11].
 70 In this regard, analyzing SDs is crucial for a complete cardiovascular clinical
 71 assessment.

72 Environmental determinants are key risk factors linked to CVDs. Although they are
 73 generally understudied and overlooked [10], growing evidence suggests that variations
 74 in factors such as temperature, altitude, climate and pollution, among others, remain
 75 significant determinants of cardiovascular risk [12,13]. Specifically, altitude continues
 76 to be a factor closely associated with cardiovascular risk. Several studies support an
 77 inverse association between altitude and cardiovascular risk factors [14–18], but the
 78 required time of exposure for a protective effect is unclear.

79 Overall, there are two scenarios, a rapid change to high altitude and a progressive
80 adaptation to it. It is well known that patients with CVDs traveling from areas at sea
81 level to the ones at high altitude –defined as the terrestrial elevation at which oxygen
82 hemoglobin saturation decreases below 90%; corresponding to an altitude of about 2500
83 m– [19] have an increased mortality risk as a consequence of lower physiological
84 reserves [20]. Several explanations have been proposed. Individuals with a reduced
85 physiological reserve and subsequent difficulty to adapt to hypoxic conditions at high
86 altitudes can present decreased functional capacity due to impaired pulmonary gas
87 exchange and/or cardiac output. However, there is scarce epidemiological data
88 discussing morbidity after traveling to altitude areas among this population [20].

89 Considering that about 400 million people live at an altitude of over 1500 meters above
90 sea level and around 150 million people live in regions higher than 2500 m [21,22],
91 altitude remains as an important health determinant that requires proper analysis. This
92 population has managed to survive at high altitudes for generations; therefore, contrary
93 to the above-mentioned statement, scientific evidence suggest that they must have
94 developed significant adaptations to lower oxygen levels to survive [13,23].

95 Long term exposure to high altitudes seems to be associated with a lower incidence of
96 obesity [14,17], high blood pressure [16,24], metabolic syndrome [15,18], diabetes [15],
97 and, even, a better expectancy of life [25]. In fact, living at a geographically higher
98 elevation was also associated with a lower risk of developing metabolic syndrome [18].
99 Specifically, no studies have focused on the association between formal cardiovascular
100 risk estimation and altitude, and most of those studies are only focusing on the
101 association between just a few categories of altitude, making it difficult to understand
102 the association and its real magnitude on a meter-by-meter basis.

103 With this background we hypothesized that altitude is inversely related with
104 cardiovascular risk. Using the databases of the Ecuadorian national health survey of
105 2012 we aimed to assess the association between altitude and cardiovascular risk among
106 the Ecuadorian adult population, of ≥ 40 to 60 years old on a meter-by-meter basis.

107 **Materials and Methods**

108 **Design**

109 Cross sectional study using data from the Ecuadorian National Health Survey (NHS) of
110 2012.

111 **Population and databases**

112 We included in our study available information of adults of ≥ 40 to 60 years old who
113 have sociodemographic, anthropometric, cardiovascular risk factors, and laboratory
114 biomarkers that were included in the in NHS in 2012 (see flowchart in the **S1 Figure**).

115 The Ecuadorian national health survey was a cross-sectional study conducted in 2012
116 which involved nationally representative samples of the civilian noninstitutionalized
117 Ecuadorian population, the details regarding the survey could be found elsewhere
118 [15,26]. The survey was conducted by the National Institute of Statistics and Census
119 using a stratified, multistage cluster design [26].

120 **Measurements**

121 We included in our analyses sex, age, ethnicity, educational level, availability of social
122 security, immigrants in family, area, income quintile, overcrowding (≥ 7 inhabitants in
123 the house), any alcohol consumption, history of hypertension, body mass index,

124 hematocrit, and triglycerides. Ethnicity was self-reported and classified as Indigenous,
125 Afroecuatorians, Montubios and Mestizos. Standardized blood pressures were obtained
126 by sphygmomanometer, and mean blood pressures from the last 2 measurements were
127 used in the Ecuadorian NHS. Blood lipids were measured enzymatically. Detailed
128 specimen collection and processing instructions are described in the NHS [26].
129 Anthropometry was assessed in a standardized way, and body mass index (BMI; in
130 kg/m^2) was calculated.

131 The main explanatory variable was altitude on a meter-by-meter assessment, using
132 information from the altitude of the housing in which survey participants lived [15,26].
133 Altitude was obtained by georeferencing, according to the methods that have been
134 described elsewhere [26].

135 **Cardiovascular Health Metrics**

136 Cardiovascular health metrics included blood pressure, blood glucose, and lipid profile.
137 High blood pressure was defined with a self-reported history of hypertension, diabetes
138 mellitus was defined when the fasting glucose was higher or equal to 126 mg/ dL [27].
139 Risk of CHD and stroke or CVD at 10 years were calculated by Framingham equations
140 (available at <http://cvrisk.mvm.ed.ac.uk/help.htm>) [28,29].

141 **Sample considerations and statistical analyses**

142 Using the prevalence of high blood pressure as the methodological variable, a random
143 sample of 3601 individuals is sufficient to estimate, with a confidence of 95% and a
144 precision of +/- 1 percentage units, a population percentage that will foreseeably be
145 around 9.3% [26]. In percentage of necessary replacements, it has been foreseen that it
146 will be 10%. The final sample was 3661 participants included in the study assuring

147 statistical power (see Figure 1 and the online supplementary material for further details)
148 (see). The sample calculation was performed using the GRANMO population calculator
149 <http://www.imim.cat/ofertadeserveis/software-public/granmo/> [30].

150 First, we tested the bivariate associations between altitude (both categorized four
151 quartiles and as continuous variables) and the percentage of cardiovascular risk (CHD,
152 Stroke and CVD) at 10 years, using analysis of variance and linear regression. Despite
153 altitude and cardiovascular risk were non-normally distributed (**S1 and S2 Figures**),
154 and prior to building multivariable models, we used generalized additive model
155 analyses to test whether the shape of the association between altitude and cardiovascular
156 risk was linear.

157 Then, we used multivariable linear regression to assess the independent effect of
158 altitude on CVD. We tested a list of potential confounders, including age, sex, ethnicity,
159 economic quintile status, social security availability, overcrowding (≥ 7 inhabitants *per*
160 home), emigration, smoking and alcohol consumption, hypertension, hematocrit, and
161 triglycerides. From these variables, we built a “saturated model”, which included: (i)
162 variables independently related to the exposure or the outcome (p -value < 0.05), or that
163 modified ($>10\%$ change in coefficient) the estimates for the remaining variables, and
164 (ii) those variables that were considered important to all researchers. Then, we built a
165 “parsimonious model” using a backward stepwise elimination process from the
166 “saturated model” removing variables (one at a time) if Wald’s p -value < 0.05 . We
167 tested both models, saturated versus parsimonious by the likelihood ratio test which was
168 used to choose the final model and for the interpretation of the results. We tested
169 goodness-of-fit of the final models.

170 We also built logistic regression models, including all significant variables that were
171 identified in the final linear regression models, using the dichotomous outcome variable
172 “high cardiovascular risk” when there was $\geq 20\%$ risk of CHD and stroke or CVD at 10
173 years.

174 We performed several sensitivity analyses. Thus, we ran the final model stratifying by
175 sex and by excluding (i) those who were living at less than 53 m (first quartile of
176 altitude), (ii) those who were living at higher areas than 2635 m (fifth quartile of
177 altitude), (iii) those with self-reported diagnosis of hypertension, and (iv) those with
178 elevated LDL cholesterol (≥ 160 mg/dL) [31].

179 To identify potential effect modification, we stratified main analyses according to sex,
180 history of hypertension, and smoking status. The analyses were performed using Stata
181 16.1 (Stata Statistical Software: Release 16.1; StataCorp LP, College Station, TX,
182 USA).

183 The NHS which we used was performed in 2012. The specific ethical issues have been
184 described elsewhere [26].

185 **Results**

186 A total of 3661 patients were included. Most patients were women (69%), with a mean
187 (SD) age of 45 (7) years, the majority were mestizo population (83%), with primary or
188 lesser education (50%), only 35% had social security, mostly from urban areas (62%).
189 The median (P25 to P75) altitude at which participants lived was 843 (53 to 2635) m.
190 Regarding harmful health-related habits, most participants (90%) stated they have
191 consumed alcohol at some point during their lifetime. There was also a tobacco
192 smoking prevalence of 45%. The prevalence of self-reported history of hypertension

193 and diabetes (as measured by fasting glucose ≥ 126 mg /dL) was 24% and 5%,
194 respectively. Mean (SD) BMI was 28 (5) kg/m², and mean total cholesterol was 196
195 (41) mg/dL (**S1 Table**). The prevalence of high ($\geq 20\%$) cardiovascular risk (stroke or
196 coronary heart disease) at 10 years was 7%.

197 In the bivariate analysis, increasing altitude was associated with lower median
198 percentage cardiovascular risk at 10 years, as it was 8% in the lowest quartile of
199 altitude (< 54 m) and 6% in the higher quartile of altitude (> 2635 m) (p -value < 0.001),
200 and with a lower median risk of stroke or coronary heart disease at 10 years, being 7%
201 in the lowest quartile of altitude (< 54 m) and 5% in the higher quartile of altitude
202 (> 2635 m) (p -value < 0.001). Additionally, in the crude linear regression model we
203 found a linear dose-response shape, with a reduction of -0.0005 percentual points in
204 CVD risk *per* each increase in a meter in the altitude at which participants live, p -
205 trend < 0.001 ; interestingly, each cardiometabolic risk factor seems to improve with
206 increasing altitude (**Table 1 and Table 2**).

207 In the multivariable saturated model [adjusted for sex, age, ethnicity, educational level,
208 availability of social security, immigrants in family, area, income quintile,
209 overcrowding (≥ 7 inhabitants in the house), any alcohol consumption, history of
210 hypertension, BMI, hematocrit, and triglycerides] participants had 0.0004 % less
211 probability of developing cardiovascular (stroke and coronary heart disease) disease at
212 10 years *per* each increase in a meter in the altitude that participants live at ($p < 0.001$)
213 (**Table 2 and Figure 1**). This association persisted in the parsimonious model ($\beta =$
214 0.0005%, $p = 0.02$). The effect of altitude on cardiovascular risk did not change after
215 stratifying by sex (**S3 Table**).

216 The exclusion of people who were living at less than 53 m of altitude, those who were

217 living at higher altitudes than 2635 m, people with self-reported diagnosis of
218 hypertension, and those with elevated LDL cholesterol (≥ 160 mg/dL) in the model did
219 not modify the estimate of the association between altitude and cardiovascular risk (**S4**
220 **Table**). Linear regression goodness of fit tests did not reveal any significant
221 abnormality.

222 **Discussion**

223 **Main findings**

224 We found that, *per* each increase of 1000 m in the altitude that people live at, there is a
225 reduction of almost half a percentual point in the cardiovascular risk at 10 years. This
226 finding could be considered of little relevance from a clinical point of view, but altitude
227 may be significant from a public health perspective, in terms of focusing with enhanced
228 strategies of health promotion and primary prevention against CVDs in the population
229 of coastal regions. In that regard, we share the criteria of Lopez-Pascual and cols. [18]
230 about the potential existence of the Rose prevention paradox, where factors that make a
231 small difference to the population distribution may be more important than factors that
232 have a clinical impact on a small number of people [27].

233 **Contrast with scientific evidence**

234 As several studies have demonstrated, altitude and specifically high altitude, is an
235 important determinant of health outcomes, including cardiovascular disease. It is known
236 that altitude-associated conditions may have different impacts on risk factors which can
237 influence the development of different diseases; as well as having consequences on life
238 expectancy and mortality [32]. For instance, a study conducted in the United States
239 concluded that altitude may have protective effects on cardiovascular diseases and

harmful effects on chronic pulmonary disease (COPD), with a dose-response relationship. Other authors [33], in a longitudinal, census-based record linkage study commented on the protective effect of living at higher altitude on coronary heart disease and stroke mortality; however, this study explained that this effect might have appeared due to climate-related factors and not necessarily due to classic cardiovascular risk factors. Another study in rural Greece concluded that living in mountainous areas have a possible protective effect from total and coronary mortality; this was explained by the possible effects of physical activity [34].

Even if a positive relation appears in some studies, a systematic review described that intermittent exposure to high altitude among workers increased the risk of CVDs. According to Burtcher, “COPD might be reduced when living at higher elevations but when suffering from COPD the mortality risk rises. Thus, COPD patients, especially when disease progresses would benefit from moving down to more oxygen rich sea level regions” [32]. As several circulatory changes occur during exposure to high altitude, some studies [19,35] concluded on the negative effect of altitude on populations suffering from pre-existing cardiovascular diseases.

It is not the first time that altitude has been linked with cardiovascular risk [17,25]. Some studies show that native Tibetans and Nepalese Sherpas rarely have systolic hypertension, having also lower levels of cholesterol [11]. A cohort study within the German-speaking part of Switzerland found a decreasing mortality by coronary heart disease or stroke when altitude increases. Some possible explanations to this finding are related to other risk factors such as pollution, since air pollution diminishes within increasing altitude. Another reason to support this fact is that diet could also be beneficial since food produced at higher altitudes might be richer in protective nutrients like omega 3 and vitamin D in dairy products [33].

265 Populations living in high lands experienced significant anatomic, physiological, and
 266 metabolic adaptation to cold temperature and low oxygen levels [13]. Other studies
 267 have suggested that living at high altitude may confer highlanders with protection
 268 against cardiovascular risk factors like dyslipidemia as well as CVDs such as
 269 hypertension and coronary ischemic disease [36,37]. The physiological changes are
 270 mostly due to ambient hypoxia, which occurs because of low atmospheric pressure,
 271 whilst the percentage of oxygen remains the same [14,38]. In Ecuador, there could also
 272 be an impact in lower cardiovascular risk, due to seasonal and latitudinal location.
 273 Studies have found that being close to the equator decreased blood pressure due to the
 274 correlation between Vitamin D absorption associated with UVB radiation [13].

275 Initial altitude-related adaptive changes include increased heart rate, cardiac output,
 276 hyperventilation, and, subsequently, increased red blood cell mass [14,19,39].
 277 Eventually, a steady state could be reached, possibly due to the beneficial effects of
 278 ensuing cardiovascular, respiratory, and muscular adaptation mechanisms. However, it
 279 is important to note that there is substantial interindividual variability in the
 280 cardiovascular response to hypoxia [19]. In a study conducted by Sherpa et al, the
 281 female individuals living at high altitude had very low coronary heart disease risk, in
 282 addition to variations in the lipid profile of their population, namely a higher prevalence
 283 of hypertriglyceridemia in men [40]. Despite there is some evidence suggesting that
 284 there is a direct association between altitude and cardiometabolic risk [19,35,41,42], our
 285 study strongly supports the idea that altitude is a determinant of cardiovascular health in
 286 an inverse association when the exposure is prolonged.

287 Regarding the association between education and cardiovascular disease, we could not
 288 corroborate that link; and, although several studies have found that lower educational
 289 level is associated with higher cardiovascular risk, this relationship may vary depending

on the analyzed cohort [43]. Furthermore, one possible explanation is that the association between education and CVD risk is mediated by obesity, metabolic syndrome, and high blood pressure [44]. Another explanation is that in Ecuador, the economic quintile could be a strong determinant of CVD risk, as it is seen in our analyses in which the poorest group had less CVD risk; thus, socioeconomic status is an important influence factor of CVD risk.

Public health implications of our findings

Even though the clinical advice to live near the sea has become popular among cardiologists and other medical specialists when a patient suffers from cardiopulmonary diseases, our study gives valuable information that could guide and further analyse the need to reconsider or personalize this advice. Clearly, for patients with cardiovascular diseases who regularly live at low altitudes, there is sufficient evidence to not recommend trips to high altitudes, given the limited cardiopulmonary reserve which could become compromised and would probably increase their CVD risk; however, after our study, we can assume that individuals residing in elevated areas have a lower risk of developing CVDs. Consequently, considerations need to be made about exposing a patient to prolonged periods of time at high altitudes to receive the benefits of the stress produced to avoid cardiovascular disease.

Currently, it is not possible to make an appropriate recommendation for individual-based benefits for at-risk population of CVDs about exposure to high altitudes, but future studies are needed to explore whether simulated altitude conditions may have potential protective, or even, therapeutic interventions for cardiovascular risk [13]. It would be important to state that people who do not have a CVD can continue living at high altitude areas to enhance other health promotion and prevention measures against

314 CVDs, contrary to the ones who have a CVD who could be advised to live at the sea
315 level to improve pulmonary health problems.

316 Perhaps in the future, this evidence could be the door towards the development of new
317 strategies for health promotion and primary prevention, possibly, also for treatments
318 stratified to the altitude of the residential areas of different populations.

319 At the same time, the strengthening of the high-altitude food systems could be a way of
320 promoting and spreading dietary practices of high-altitude regions. Mediterranean diet
321 has been popularized among physicians, but it has serious limitations regarding its cost
322 and availability in low- and middle-income countries like Ecuador. This study could be
323 a useful element to think about promoting public health measures aimed to improve
324 conditions for groups living in low-altitude areas. For example, to improve access to
325 nutrients and educational policies directed to provide conditions to reduce the risk of
326 CVDs, among others.

327 **Strengths and limitations**

328 We are aware that this is a cross sectional study; therefore, it is not possible to establish
329 a causal relationship between altitude and cardiovascular risk. At the same time, this is
330 the first study, to our knowledge, which considered the impact of altitude on a meter-
331 by-meter basis and its relation on formally calculated cardiovascular risk. In addition,
332 this study considers the potential residual confounders of several factors from social
333 demographic, economic, biochemical, and anthropometric measures, reducing the risk
334 of confounding bias.

335 Regarding the possibility of residual confounding of physical activity (PA) in the
336 association between altitude and CVDs risk, the amount of PA across altitude strata

could be different, researchers have described significant adaptations to high altitude, in terms of body weight reduction, regardless of the amount of performed PA [45]; therefore, we do not believe that this is a significant source of bias. Even though we did not include PA in our analyses, the potential protective interaction between altitude and physical activity is an interesting hypothesis that goes far beyond this present study.

We could not separate the individuals and the coexistence of CVD, but when assessing the association excluding those with history of high blood pressure or highest values of cholesterol the association remained.

Other sources of potential residual confounding were the lack of information about pollution, humidity, temperature, and green space exposure. But, to our knowledge, most of those potential determinants of cardiovascular risk could not act as significant confounders as we found that the association was significant in all the sensitivity analyses.

Another limitation is related to the main quantitative nature of the study. Qualitative or mixed-methods tools could give an added value to the interpretation of the results as they provide further details of people's lifestyles, behaviours, and contexts.

In addition, we did not consider the effects and/or interactions of place of birth and climate related determinants, as it was impossible to determine them within the available survey data. As a previous study indicated [33], being born at altitudes higher or lower than the place of residence was associated with lower or higher risk. Additionally, other studies elucidated on the effects of climate related factors such as temperature and levels of ultraviolet radiation [46] which have a possible negative effect on cardiovascular mortality. Consequently, including these factors in further research,

360 could provide a better understanding of the risks, particularly important to the
361 populations inhabiting the Andes.

362 Finally, information on food intake was not included in the survey questionnaire and
363 information on occupation was not systematically collected. In the US population, the
364 inverse association between altitude and obesity remained while adjusting for fruit and
365 vegetable consumption [14].

366 **Suggestions for future research**

367 It is necessary to elucidate on the epigenetic, molecular, and physiologic pathways to
368 achieve protection against CVDs among people who live at higher altitudes. Regarding
369 those protective mechanisms, several explanations have been proposed.

370 First, a study focused on assessing the effect of altitude training at 1600 and 1800 m
371 showed larger improvements in performance after altitude training. It may be due to the
372 greater overall load of training in hypoxia compared with normoxia, combined with a
373 hypoxia-mediated increase in hemoglobin mass [47]. Nevertheless, there is uncertainty
374 about the optimal timeframe for peak performances, suggesting that that the optimal
375 window to improve physical performance is individual, and factors other than altitude
376 exposure per se may be important.

377 Second, it is also possible that other factors such as polymorphisms for high altitude
378 adaptation were involved in this effect, Valverde and cols. identified a number of single
379 nucleotide polymorphisms (SNPs) exhibiting large allele frequency differences over
380 900,000 genotyped SNPs. A region in chromosome 10 (within the cytogenetic bands
381 q22.3 and q23.1) was significantly differentiated between highland and lowland groups
382 [48], interestingly, the results suggest that positive selection on the enhancer might

383 increase the expression of this antioxidant, and thereby prevent oxidative damage. In
384 addition, the most significant signal in a relative extended haplotype homozygosity
385 analysis was localized to the SFTPD gene, which encodes a surfactant pulmonary-
386 associated protein involved in normal respiration and innate host defence.

387 We believe that several potential issues to investigate would be relevant soon. There is a
388 possibility that altitude induces expression of certain genes related to protective
389 mechanisms against cardiovascular disease.

390 Moreover, we raised the question about how altitude could contribute to enhance the
391 effects of population density-related features (pollution from urban areas, migrations or
392 food accessibility) [18], several behavioural changes or treatments for primary
393 prevention of cardiovascular risk and, even, for cardiovascular disease. In that regard,
394 mortality may be profoundly modified by the complex interactions between behavioral
395 and environmental conditions.

396 **Conclusion**

397 From a public health perspective, altitude at which individuals live is an important
398 health determinant of cardiovascular risk; specifically, *per* each increase of 1000 m in
399 the altitude that people live at, there is a reduction of almost half a percentual point in
400 the cardiovascular risk at 10 years. It is important to consider that living in the
401 highlands could be a protective factor related to a reduced cardiovascular risk, but this
402 effect could be not as relevant from a clinical perspective than from a public health
403 point of view. Further research is necessary to understand genetics, epigenetic, and
404 molecular mechanisms that explain this finding; complemented by further analyses on
405 environmental, climate and behavioural factors.

407 **Acknowledgments**

408 Authors thank the input from the “Cardiovascular Risk Score” project members. We,
409 also, acknowledge the contributions from the *Instituto de Salud Pública* from PUCE.

410 **Author Contributions**

411 Conceptualization: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela León-
412 Cáceres, Luciana Armijos-Acurio, and Iván Dueñas-Espín

413 Data curation: Carmenza Sevilla and Iván Dueñas-Espín

414 Formal analysis: Iván Dueñas-Espín

415 Funding acquisition: Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor,
416 Hugo Pereira-Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez,
417 Carmenza Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván
418 Dueñas-Espín.

419 Investigation: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela León-
420 Cáceres, Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor, Hugo Pereira-
421 Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez, Carmenza
422 Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván Dueñas-Espín.

423 Methodology: Iván Dueñas-Espín.

424 Project administration: Iván Dueñas-Espín.

425 Writing – original draft: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela
426 León-Cáceres, and Iván Dueñas-Espín.

427 Writing – review & editing: Andrea Cevallos Guerrero, Heidi Angela Fernández,
 428 Ángela León-Cáceres, Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor,
 429 Hugo Pereira-Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez,
 430 Carmenza Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván
 431 Dueñas-Espín.

432

433 **References**

- 434 1. World Health Organization. Global Status Report On Noncommunicable
435 Diseases 2014. 2014;
- 436 2. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP,
437 et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the
438 American Heart Association. Vol. 139, Circulation. 2019. 56–528 p.
- 439 3. Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S,
440 et al. The Global Economic Burden of Noncommunicable Diseases.
441 2011;(September).
- 442 4. World Health Organization (WHO). Cardiovascular diseases (CVDs) [Internet].
443 2017 [cited 2021 Apr 13]. Available from: [https://www.who.int/en/news-](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
444 room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- 445 5. Berra K, Fletcher B, Hayman LL, Miller NH. Global cardiovascular disease
446 prevention: A call to action for nursing executive summary. J Cardiovasc Nurs.
447 2013;28(6):505–13.
- 448 6. Martínez-García M, Salinas-Ortega M, Estrada-Arriaga I, Hernández-Lemus E,
449 García-Herrera R, Vallejo M. A systematic approach to analyze the social
450 determinants of cardiovascular disease. PLoS One. 2018;13(1):1–25.
- 451 7. Roux AVD, Merkin SS, Arnett D, Chambless L, Massing M, Nieto FJ, et al.
452 Neighborhood of Residence and Incidence of Coronary Heart Disease. N Engl J
453 Med. 2001 Jul;345(2):99–106.
- 454 8. Havranek EP, Mujahid MS, Barr DA, Blair I V., Cohen MS, Cruz-Flores S, et al.
455 Social determinants of risk and outcomes for cardiovascular disease: A scientific

- statement from the American Heart Association. *Circulation*. 2015;132(9):873–98.
9. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. *Nat Rev Cardiol*. 2015 Sep;12(9):508–30.
10. Baumgartner J, Brauer M, Ezzati M. The role of cities in reducing the cardiovascular impacts of environmental pollution in low- and middle-income countries. 2020;1–11.
11. Kretsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. *Can J Cardiol* [Internet]. 2010;26(SUPPL. C):8C-13C. Available from: [http://dx.doi.org/10.1016/S0828-282X\(10\)71075-8](http://dx.doi.org/10.1016/S0828-282X(10)71075-8)
12. Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease. *J Am Coll Cardiol*. 2018 Oct;72(17):2054–70.
13. Bhatnagar A. Environmental Determinants of Cardiovascular Disease. Vol. 121, *Circulation Research*. 2017. p. 162–80.
14. Woolcott OO, Gutierrez C, Castillo OA, Elashoff RM, Stefanovski D, Bergman RN. Inverse association between altitude and obesity: A prevalence study among andean and low-altitude adult individuals of Peru. *Obesity*. 2016;24(4):929–37.
15. Pérez-Galarza J, Baldeón L, Franco OH, Muka T, Drexhage HA, Voortman T, et al. Prevalence of overweight and metabolic syndrome, and associated sociodemographic factors among adult Ecuadorian populations: the ENSANUT-ECU study. *J Endocrinol Invest* [Internet]. 2021;44(1):63–74. Available from: <https://doi.org/10.1007/s40618-020-01267-9>

- 479 16. Song C, Chongsuvivatwong V, Zhu Luo Bu O, Ji D, Sang Zhuo Ma B, Sriplung
480 H. Relationship between hypertension and geographic altitude: a cross-sectional
481 survey among residents in Tibet. *J Int Med Res.* 2020;48(2).
- 482 17. Pajuelo-Ramírez J, Torres-Aparcana H, Agüero-Zamora R, Quispe AM. Altitude
483 and its inverse association with abdominal obesity in an andean country: A cross-
484 sectional study [version 1; peer review: 2 approved, 1 not approved].
485 *F1000Research.* 2019;8:1–17.
- 486 18. Lopez-Pascual A, Bes-Rastrollo M, Sayón-Orea C, Perez-Cornago A, Díaz-
487 Gutiérrez J, Pons JJ, et al. Living at a geographically higher elevation is
488 associated with lower risk of metabolic syndrome: Prospective analysis of the
489 SUN cohort. *Front Physiol.* 2017;7(JAN):1–9.
- 490 19. Rimoldi SF, Sartori C, Seiler C, Delacrétaiz E, Mattle HP, Scherrer U, et al. High-
491 altitude exposure in patients with cardiovascular disease: Risk assessment and
492 practical recommendations. *Prog Cardiovasc Dis* [Internet]. 2010;52(6):512–24.
493 Available from: <http://dx.doi.org/10.1016/j.pcad.2010.03.005>
- 494 20. Seccombe LM, Peters MJ. Physiology in medicine: Acute altitude exposure in
495 patients with pulmonary and cardiovascular disease. *J Appl Physiol.*
496 2014;116(5):478–85.
- 497 21. Niermeyer S, Mollinedo PA, Huicho L. Child health and living at high altitude.
498 Vol. 94, *Archives of Disease in Childhood.* 2009. p. 806–11.
- 499 22. Huddleston B, de Salvo EAP, Zanetti M, Bloise M, Bel J, Franceschini G, et al.
500 Towards a GIS-based analysis of mountain environments and populations
501 [Internet]. *Environment and Natural Resources working paper No. 10.* 2003
502 [cited 2021 Apr 13]. Available from: <http://www.fao.org/family->

503 farming/detail/en/c/285416/

504 23. Savla JJ, Levine BD, Sadek HA. The Effect of Hypoxia on Cardiovascular
505 Disease: Friend or Foe? High Alt Med Biol. 2018;19(2):124–30.

506 24. Mingji C, Onakpoya IJ, Perera R, Ward AM, Heneghan CJ. Relationship
507 between altitude and the prevalence of hypertension in Tibet: A systematic
508 review. Heart. 2015;101(13):1054–60.

509 25. Ezzati M, Horwitz MEM, Thomas DSK, Friedman AB, Roach R, Clark T, et al.
510 Altitude, life expectancy and mortality from ischaemic heart disease, stroke,
511 COPD and cancers: National population-based analysis of US counties. J
512 Epidemiol Community Health. 2012;66(7).

513 26. Freire W, Ramírez-Luzuriaga M, Belmont P, Mendieta M, Silva-Jaramillo M,
514 Romero N, et al. Instituto Nacional de Estadística y Censos INEC, Ministerio de
515 Salud Pública MSP. Encuesta Nacional de salud y Nutrición. ENSANUT-ECU
516 2012. Quito-Ecuador: Ministerio de Salud Pública. Instituto Nacional de
517 Estadísticas y Censos; 2014. p. 112.

518 27. Statements P. Standards of medical care in diabetes - 2012. Diabetes Care.
519 2012;35(SUPPL. 1).

520 28. Anderson KM, Odell PM, Wilson PWF, William B. Kannel M. Cardiovascular
521 disease risk profiles. Am Heart J. 1991;(1).

522 29. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham,
523 QRISK and others: How to choose. Heart. 2011;97(6):442–4.

524 30. Marrugat J, Vila J, Pavesi M, Sanz F. [Estimation of the sample size in clinical
525 and epidemiological investigations]. Med Clin (Barc) [Internet]. 1998 Sep

- 12;111(7):267–76. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/9789243>
31. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCN
A Guideline on the Management of Blood Cholesterol: A Report of the American
College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. Vol. 139, Circulation. 2019. 1082–1143 p.
32. Burtcher M. Effects of living at higher altitudes on mortality: A narrative
review. Aging Dis. 2014;5(4):274–80.
33. Faeh D, Gutzwiller F, Bopp M. Lower mortality from coronary heart disease and
stroke at higher altitudes in Switzerland. Circulation. 2009;120(6):495–501.
34. Baibas N, Trichopoulou A, Voriadis E, Trichopoulos D. Residence in
mountainous compared with lowland areas in relation to total and coronary
mortality. A study in rural Greece. J Epidemiol Community Health. 2005;59(4):274–8.
35. Hultgren HN. Effects of altitude upon cardiovascular diseases. J Wilderness Med
[Internet]. 1992;3(3):301–8. Available from: <http://dx.doi.org/10.1580/0953-9859-3.3.301>
36. Corante N, Anza-Ramírez C, Figueroa-Mujica R, MacArlupú JL, Vizcardo-
Galindo G, Bilo G, et al. Excessive Erythrocytosis and Cardiovascular Risk in
Andean Highlanders. High Alt Med Biol. 2018;19(3):221–31.
37. Negi PC, Bhardwaj R, Kandoria A, Asotra S, Ganju N, Marwaha R, et al.

549 Epidemiological study of hypertension in natives of Spiti valley in Himalayas
550 and impact of hypobaric hypoxemia; A cross-sectional study. J Assoc Physicians
551 India. 2012;60(6):21–5.

552 38. Azad P, Zhao HW, Cabrales PJ, Ronen R, Zhou D, Poulsen O, et al. Senp1 drives
553 hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Monge's
554 disease. J Exp Med. 2016;213(12):2729–44.

555 39. Naeije R, De Backer D, Vachiéry JL, De Vuyst P. High-altitude pulmonary
556 edema with primary pulmonary hypertension. Chest [Internet]. 1996;110(1):286–
557 9. Available from: <http://dx.doi.org/10.1378/chest.110.1.286>

558 40. Sherpa LY, Deji, Stigum H, Chongsuvivatwong V, Thelle DS, Bjertness E.
559 Obesity in Tibetans aged 30–70 living at different altitudes under the North and
560 South faces of Mt. Everest. Int J Environ Res Public Health. 2010;7(4):1670–80.

561 41. Miele CH, Schwartz AR, Gilman RH, Pham L, Wise RA, Davila-Roman VG, et
562 al. Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude.
563 High Alt Med Biol. 2016;17(2):93–100.

564 42. Aryal N, Weatherall M, Bhatta YKD, Mann S. Blood pressure and hypertension
565 in people living at high altitude in Nepal. Hypertens Res [Internet].
566 2019;42(2):284–91. Available from: <http://dx.doi.org/10.1038/s41440-018-0138->
567 x

568 43. Assari S, Nikahd A, Malekahmadi MR, Lankarani MM, Zamanian H. Race by
569 Gender Group Differences in the Protective Effects of Socioeconomic Factors
570 Against Sustained Health Problems Across Five Domains. J Racial Ethn Heal
571 Disparities [Internet]. 2017;4(5):884–94. Available from:
572 <http://dx.doi.org/10.1007/s40615-016-0291-3>

- 573 44. Dégano IR, Marrugat J, Grau M, Salvador-González B, Ramos R, Zamora A, et
574 al. The association between education and cardiovascular disease incidence is
575 mediated by hypertension, diabetes, and body mass index. *Sci Rep*. 2017;7(1):1–
576 8.
- 577 45. Zaccagni L, Barbieri D, Cogo A, Gualdi-Russo E. Anthropometric and body
578 composition changes during expeditions at high altitude. *High Alt Med Biol*.
579 2014;15(2):176–82.
- 580 46. Burtcher M, Burtcher J. Concerning the article recently published in this
581 Journal by Aryal and colleagues entitled, “Blood pressure and hypertension in
582 people living at high altitude in Nepal.” *Hypertens Res* [Internet].
583 2019;42(7):1095. Available from: <http://dx.doi.org/10.1038/s41440-019-0241-7>
- 584 47. Sharma AP, Saunders PU, Garvican-Lewis LA, Clark B, Welvaert M, Gore CJ,
585 et al. Improved performance in national-level runners with increased training
586 load at 1600 and 1800 m. *Int J Sports Physiol Perform*. 2019;14(3):286–95.
- 587 48. Valverde G, Zhou H, Lippold S, De Filippo C, Tang K, Herráez DL, et al. A
588 novel candidate region for genetic adaptation to high altitude in Andean
589 populations. *PLoS One*. 2015;10(5):1–22.

590

591 Tables and Figures

592 Table 1. Description of the sample across altitude categories.

Variable	Altitude in m (n = 3661)				p-value
	0 to 53 n=919	54 to 843 n=914	844 to 2635 n=914	2636 to 3834 n=914	
Female sex, n (%)	604 (24)	634 (25)	647 (26)	647 (26)	0.061**
Age, mean (SD)	46 (7)	44 (8)	45 (7)	45 (7)	<0.001*
Ethnicity					
Indigenous, n (%)	11 (3)	107(32)	83 (25)	136 (40)	<0.001**
Afroecuadorians, n (%)	89 (56)	47 (29)	11 (7)	13 (8)	
Montubio, n (%)	61 (50)	54 (44)	3 (2)	4 (3)	
Mestizo, n (%)	758 (25)	706 (23)	817 (27)	761 (25)	
Education level					
Higher than secondary education, n %	198 (33)	92 (15)	159 (27)	147 (25)	<0.001**
Secondary education, n %	342 (27)	307 (25)	312 (25)	283 (23)	
Primary or lesser education, n %	379 (21)	515 (28)	443 (24)	484 (27)	
Social security availability, n (%)	318 (25)	299 (24)	347 (27)	300 (24)	0.063**
Any immigrant in the family (no immigrant is the ref.)	8 (12)	10 (15)	22 (33)	27 (40)	0.001**
Rural area (urban is the ref)	161 (12)	442 (32)	366 (26)	423 (30)	<0.001**
Income quintiles					
First quintile (the poorer group), n (%)	146 (18)	271 (34)	175 (22)	210 (26)	<0.001**
Second quintile, n (%)	157 (22)	241 (33)	181(25)	141(20)	
Third quintile, n (%)	209 (29)	210 (29)	168 (23)	139 (19)	
Fourth quintile, n (%)	237(33)	120 (17)	179 (25)	177 (25)	
Fifth quintile (the richest), n (%)	168 (24)	70 (10)	211(30)	247(35)	
≥ 7 members in the family, n (%)	130 (21)	212 (35)	136 (22)	133 (22)	<0.001**
Harmful habits					
Alcohol consumption, n (%)	839 (26)	799 (24)	823 (25)	806 (25)	0.041**
Tobacco smoking, n (%)	452 (28)	407 (25)	415 (25)	369 (22)	<0.002**
Comorbidities					
History of hypertension, n (%)	675 (24)	664 (24)	712 (26)	713 (26)	0.014*
History of diabetes, n (%)	848 (24)	867 (25)	880 (25)	885 (25)	<0.001*
Anthropometry					
Weight in Kg, mean (SD)	69 (13)	69 (13)	68 (12)	66 (12)	<0.001*
Height in cm, mean (SD)	156 (9)	156 (9)	154 (8)	154 (8)	0.119*
BMI in Kg/m2, mean (SD)	28.36 (5)	28.29 (5)	28.58 (4)	27.90 (4)	<0.001*
≥18.5 to <25, n (%)	202 (26)	204 (26)	167 (22)	199 (26)	0.087
<18, n (%)	6 (35)	3 (18)	3 (18)	5 (29)	
25 to <30, n (%)	376 (25)	346 (23)	400 (26)	409 (27)	
≥ 30, n (%)	277 (26)	258 (25)	278 (27)	237 (23)	
Systolic pressure, mean (SD)	125 (17)	122 (16)	121 (16)	121 (15)	0.001*
Diastolic pressure, mean (SD)	77 (10)	76 (11)	75 (10)	75 (10)	0.057*
Laboratory Tests					
Hematocrit in %, mean (SD)	41 (4)	41 (4)	43 (4)	45 (4)	0.633*
Glucose in mg/dL, mean (SD)	105 (50)	95 (34)	93 (34)	94 (28)	<0.001*
Total cholesterol in mg/dL, mean (SD)	201 (46)	193 (39)	195 (39)	197 (39)	<0.001*

<i>LDL in mg/dL, mean (SD)</i>	123 (36)	116 (33)	118 (32)	119 (33)	<0.001*
<i>HDL in mg/dL, mean (SD)</i>	47 (13)	45 (13)	45 (13)	46 (14)	0.030*
<i>Triglycerides in mg/dL, mean (SD)</i>	163 (165)	166 (125)	169 (152)	167 (118)	<0.001*
Cardiovascular risk at 10 years in %					
<i>Risk of CVD, P50 (P25 to P75)</i>	8 (4 to 15)	7 (4 to 15)	7 (3 to 13)	6 (3 to 12)	<0.001***
<i>Risk of stroke or CHD, P50 (P25 to P75)</i>	7 (3 to 13)	5 (3 to 11)	6 (3 to 10)	5 (3 to 10)	<0.001***
Notes: * ANOVA ** Chi2 *** Kruskal Wallis Abbreviations: CI, confidence interval; N/A, not applicable, CHD, coronary heart disease; CVD, cardiovascular disease; BMI, body mass index					

593

594 Table 2. Crude and adjusted associations between altitude and the risk of stroke and/or CHD at 10 years (linear regression model).

Variable	Crude		Adjusted			
	β (95% CI)	p-value	Saturated Model* β (95% CI)	p-value	Parsimonious Model** β (95% CI)	p-value
Constant	N/A	-	14.22 (11.68 to 16.76)	<0.001	13.62 (12.62 to 14.67)	<0.001
Altitude (per each extra meter)	-0.0005 (-0.0007 to -0.0003)	<0.001	-0.0004 (-0.0006 to -0.0003)	<0.001	-0.0005 (-0.0006 to -0.0003)	<0.001
Female (male is the ref.)	-8.04 (-8.46 to -7.61)	<0.001	-6.23 (-6.63 to -5.83)	<0.001	-6.24 (-6.64 to -5.84)	<0.001
Age (per each extra year)	0.69 (0.65 to 0.74)	<0.001	0.60 (0.57 to 0.63)	<0.001	0.59 (0.56 to 0.62)	<0.001
Ethnicity						
Indigenous (ref.)	N/A	-	N/A	-	N/A	-
Afroecuadorians	2.73 (1.32 to 4.14)	<0.001	0.93 (0.04 to 1.82)	0.042	0.96 (0.07 to 1.85)	0.035
Montubio	3.7 (2.16 to 5.20)	<0.001	0.52 (-0.44 to 1.47)	0.287	0.51 (-0.44 to 1.46)	0.295
Mestizo	2.90 (2.04 to 3.76)	<0.001	0.91 (0.35 to 1.47)	<0.001	0.94 (0.38 to 1.49)	0.001
Education level						
Higher than secondary education (ref.)	N/A	-	N/A	-	N/A	-
Secondary education	-0.07 (-0.79 to 0.64)	0.841	-0.09 (-0.55 to 0.37)	0.697	-	-
Less than Primary education	0.01 (-0.66 to 0.68)	0.972	-0.36 (-0.85 to 0.13)	0.151	-	-
Social security availability (not having is the ref.)	1.24 (0.74 to 1.73)	<0.001	-0.42 (-0.74 to -0.10)	0.010	-0.40 (-0.71 to -0.09)	0.011
Any immigrant in the family (no immigrant is the ref.)	-0.65 (-2.41 to 1.10)	0.465	0.05 (-1.02 to 1.11)	0.931	-	-
Rural area (urban is the ref)	-0.99 (-1.48 to -0.50)	<0.001	-0.22 (-0.58 to 0.14)	0.225	-	-
Income quintile						
First quintile (the poorer group is the ref.)	N/A	-	N/A	-	N/A	-
Second quintile	2.02 (1.27 to 2.77)	<0.001	0.83 (0.36 to 1.30)	0.001	0.91 (0.45 to 1.38)	<0.001
Third quintile	2.38 (1.63 to 3.12)	<0.001	0.81 (0.31 to 1.31)	0.002	0.99 (0.52 to 1.46)	<0.001
Fourth quintile	2.21 (1.47 to 2.96)	<0.001	0.65 (0.12 to 1.19)	0.017	0.92 (0.44 to 1.40)	<0.001
Fifth quintile (the richest)	1.91 (1.16 to 2.65)	<0.001	0.93 (0.34 to 1.51)	0.002	1.29 (0.80 to 1.77)	<0.001
≥ 7 members in the family (otherwise is the ref.)	-0.38 (-1.02 to 0.25)	0.238	0.01 (-0.39 to 0.40)	0.971	-	-
Any alcohol consumption	3.36 (2.56 to 4.16)	<0.001	0.90 (0.40 to 1.40)	<0.001	0.89 (0.39 to 1.39)	<0.001

(otherwise is the ref.)						
History of hypertension	2.64 (2.10 to 3.19)	<0.001	1.50 (1.15 to 1.84)	<0.001	1.50 (1.16 to 1.84)	<0.001
BMI, in Kg/m ²						
≥18.5 to <25 (ref.)	N/A	-	N/A	-	N/A	-
<18	-2.30 (-5.66 to 1.06)	0.181	-1.17 (-3.21 to 0.87)	0.262	-1.11 (-3.15 to 0.93)	0.287
25 to <30	1.75 (1.14 to 2.35)	<0.001	1.19 (0.81 to 1.56)	<0.001	1.19 (0.82 to 1.56)	<0.001
≥30	2.31 (1.66 to 2.96)	<0.001	1.97 (1.55 to 2.38)	<0.001	1.97 (1.56 to 2.38)	<0.001
Hematocrit (per each extra % point)	0.58 (0.53 to 0.63)	<0.001	0.14 (0.09 to 0.18)	<0.001	0.14 (0.09 to 0.18)	<0.001
Triglycerides (per each extra unit in mg/dL)	0.02 (0.02 to 0.02)	<0.001	0.02 (0.01 to 0.02)	<0.001	0.02 (0.01 to 0.02)	<0.001
<p>Notes:</p> <p>* The value of the constant is the percentage of stroke risk and CHD at 10 years (according to Framingham equation) of a patient who lives in a mean altitude, is an indigenous person, not having social security, has higher than secondary education, who lives in an urban context, in who belongs to the first economic quintile, who has emigrant relatives, who lives with <7 persons, who does not drink alcohol, and did not reported high blood pressure as a medical diagnosis, has body mass index between 18.5 to <25 Kg/m², has a mean hematocrit, and mean triglycerides concentration.</p> <p>** The value of the constant is the percentage of risk of stroke and CHD at 10 years (according to Framingham equation) of a patient who lives in a mean altitude, is an indigenous person, has higher than secondary education, who belongs to the first economic quintile, who does not drink alcohol, and did not reported high blood pressure as a medical diagnosis, has body mass index between 18.5 to <25 Kg/m², has a mean hematocrit, and mean triglycerides concentration.</p> <p>Abbreviations:</p> <p>CI, confidence interval; N/A, not applicable, CHD, coronary heart disease; CVD, cardiovascular disease; BMI, body mass index</p>						

596 Figure 1. Adjusted odds ratios of high risk ($\geq 20\%$) of stroke and/or CHD and high risk
597 of CVD at 10 years by altitude categories, according to two multivariate logistic
598 regression models, considering the reference an altitude of the residence of <54 m.

599

600

601 **Supporting information**

602 **S1 Fig. Flowchart diagram.**

603 **S2 Fig. Histogram of altitude.**

604 **S3. Fig. Histogram of Cardiovascular risk at ten years of stroke and coronary**
605 **heart disease.**

606 **S1 Table. Characteristics of 3661 participants of Ecuadorian NHS included in the**
607 **analyses.**

608 **S2 Table. Crude and adjusted Odds Ratios of high cardiovascular risk, calculated**
609 **by four different equations, across altitude strata, according to multivariate**
610 **logistic regression models.**

611 **S3 Table. Crude and adjusted associations between altitude and the risk of stroke**
612 **and/or CHD at 10 years (linear regression model) stratified by sex.**

613 **S4 Table. Crude and adjusted associations between altitude and the risk of stroke**
614 **and/or CHD at 10 years (linear regression models) excluding: (i) those who were**
615 **living less than 53 m, (ii) those who were living higher than 2635 m, (iii) those with**
616 **self-reported diagnosis of hypertension, and (iv) those with elevated LDL**
617 **cholesterol (≥ 160 mg/dL).**